Flynn, Bernard Luke,Paul, Dharam,Harvey, Andrew John,Sethuraman, Vasu V.,Forslund, Raymond E.,Xue, Song,Livingston, Rob,Hashash, Ahmad
申请号：
AU2017201916
公开号：
AU2017201916B2
申请日:
2017.03.21
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
#$%^&*AU2017201916B220180927.pdf#####Abstract The present invention provides amorphous and crystalline forms of 1 -ethyl-6(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co-crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystalline forms, and salts, cocrystals, and pharmaceutical compositions thereof. 0 0 H N N 0 N N 1
